| BID | 0.00 | ASK | 0.00 | ||
| Open | 0.00 | Previous Close | 5.00 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | - | Analyst Rating | — — 0.00 | |
| Potential % | - | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 0.00 | Earnings Rating | — | |
| Market Cap | 39.24M | Earnings Date | - | |
| Alpha | Standard Deviation | |||
| Beta |
Today's Price Range 0.000.00 | 52W Range 0.000.00 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Neutral |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | - | |||
ROE last 12 Months | - | |||
ROA (5Y Avg) | - | |||
ROA last 12 Months | - | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | - | |||
Return on invested Capital Q | - | |||
Return on invested Capital Y | - | |||
Assets Turnover | - | |||
Receivables Turnover | - |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Leverage Ratio | - |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | - |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 0 |
| Shares Outstanding | 7.85K |
| Shares Float | 0 |
| Trades Count | 0 |
| Dollar Volume | 0 |
| Avg. Volume | 0 |
| Avg. Weekly Volume | 0 |
| Avg. Monthly Volume | 0 |
| Avg. Quarterly Volume | 0 |
Alopexx Inc Com (NASDAQ: ALPX) stock closed at per share at the end of the most recent trading day (a % change compared to the prior day closing price) with a volume of 0.0000 shares and market capitalization of 39.24M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 0 people. Alopexx Inc Com CEO is Daniel R. Vlock.
The one-year performance of Alopexx Inc Com stock is %, while year-to-date (YTD) performance is %. ALPX stock has a five-year performance of %. Its 52-week range is between and , which gives ALPX stock a 52-week price range ratio of %
Alopexx Inc Com currently has a PE ratio of -, a price-to-book (PB) ratio of -, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -%, a ROC of -% and a ROE of -%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $- revenue per share.
Of the last four earnings reports from Alopexx Inc Com, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Alopexx Inc Com’s next earnings report date is -.
The consensus rating of Wall Street analysts for Alopexx Inc Com is — (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Alopexx Inc Com stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Alopexx Inc Com has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Alopexx Inc Com has a Neutral technical analysis rating based on Technical Indicators (), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Alopexx Inc Com in the last 12-months were:
Alopexx Inc Com
Alopexx Inc is a clinical-stage biotechnology company developing novel immune therapeutics for the prevention, treatment and mitigation of bacterial, fungal, and parasitic infections that express the antigenic target poly N-acetyl glucosamine.
CEO: Daniel R. Vlock
Telephone: +1 617 780-1598
Address: 186 Alewife Brook Parkway, Cambridge 02138, MA, US
Number of employees: 0
